Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
21 hedge funds and large institutions have $894K invested in Interpace Biosciences, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
11% more funds holding
Funds holding: 19 → 21 (+2)
51% less capital invested
Capital invested by funds: $1.84M → $894K (-$942K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$77.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$16.7K |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$8.68K |
| 4 |
Renaissance Technologies
New York
|
+$6.55K |
| 5 |
Goldman Sachs
New York
|
+$1.13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$89.6K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.76K |
| 3 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$1.35K |
| 4 |
Bank of New York Mellon
New York
|
-$691 |
| 5 |
Morgan Stanley
New York
|
-$28 |
IDXG Hedge Fund Activity: Q3 2016 in Review
21 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q3 2016, worth a combined $894K — down 51% from $1.84M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new IDXG positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $77.5K. The largest seller was Dimensional Fund Advisors, cutting an estimated $89.6K.
- 21 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q3 2016, up from 19 in Q2 2016.
- Funds reported $894K of Interpace Biosciences, Inc. Common Stock stock for Q3 2016, down 51% quarter-over-quarter.
- 4 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q3 2016 and 2 closed out, a net change of +2 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q3 2016 was Virtu KCG Holdings, an estimated $77.5K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q3 2016 was Dimensional Fund Advisors, an estimated $89.6K sold.
Based on aggregated 13F filings for Q3 2016.